As of June 13, 2025, CardioGenics Holdings Inc (CGNH) reports a ROA (Return on Assets) of -826.25%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of CardioGenics Holdings Inc's ROA (Return on Assets)
Over recent years, CardioGenics Holdings Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2015-10-31 | -826.25% |
| 2014-10-31 | -992.81% |
| 2013-10-31 | -532.65% |
| 2012-10-31 | -342.41% |
| 2011-10-31 | -491.19% |
This slight downward trend highlights how CardioGenics Holdings Inc manages its efficiency in using assets to generate earnings over time.
Comparing CardioGenics Holdings Inc's ROA (Return on Assets) to Peers
To better understand CardioGenics Holdings Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| CardioGenics Holdings Inc (CGNH) | -826.25% |
| Protalix Biotherapeutics Inc (PLX) | 3.99% |
| Forward Pharma A/S (FWP) | -2.65% |
| Globeimmune Inc (GBIM) | -24.05% |
| Constellation Pharmaceuticals Inc (CNST) | -28.59% |
| Sangui Biotech International Inc (SGBI) | -45.35% |
Compared to its competitors, CardioGenics Holdings Inc's ROA (Return on Assets) is among the lowest compared to peers, suggesting potential inefficiency in asset utilization.